Stem cell therapy for heart failure

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These "first-generation" clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.

Original languageEnglish (US)
Pages (from-to)187-194
Number of pages8
JournalMethodist DeBakey cardiovascular journal
Volume9
Issue number4
StatePublished - 2013

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Heart Failure
Clinical Trials
Bone Marrow
Chemokines
Cardiac Myocytes
Blood Vessels
Publications
Intercellular Signaling Peptides and Proteins
Fibrosis
Apoptosis
Cytokines

Keywords

  • heart failure
  • regenerative medicine
  • stem cell therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stem cell therapy for heart failure. / Michler, Robert E.

In: Methodist DeBakey cardiovascular journal, Vol. 9, No. 4, 2013, p. 187-194.

Research output: Contribution to journalArticle

@article{d5829bb583a740adbc8efc0b9cf25214,
title = "Stem cell therapy for heart failure",
abstract = "The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These {"}first-generation{"} clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.",
keywords = "heart failure, regenerative medicine, stem cell therapy",
author = "Michler, {Robert E.}",
year = "2013",
language = "English (US)",
volume = "9",
pages = "187--194",
journal = "Methodist DeBakey cardiovascular journal",
issn = "1947-6094",
publisher = "Methodist DeBakey Heart & Vascular Center",
number = "4",

}

TY - JOUR

T1 - Stem cell therapy for heart failure

AU - Michler, Robert E.

PY - 2013

Y1 - 2013

N2 - The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These "first-generation" clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.

AB - The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These "first-generation" clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.

KW - heart failure

KW - regenerative medicine

KW - stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=84918528597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918528597&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 187

EP - 194

JO - Methodist DeBakey cardiovascular journal

JF - Methodist DeBakey cardiovascular journal

SN - 1947-6094

IS - 4

ER -